Oncocyte to Announce First Quarter 2022 Financial Results
28 avr. 2022 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™
27 avr. 2022 16h30 HE
|
Oncocyte Corporation
IRVINE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
13 avr. 2022 22h01 HE
|
Oncocyte Corporation
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today the pricing of an underwritten public offering of 26,266,417...
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
13 avr. 2022 17h12 HE
|
Oncocyte Corporation
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today that it has commenced an underwritten public offering of shares...
Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
13 avr. 2022 17h10 HE
|
Oncocyte Corporation
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company with the mission to improve patient outcomes by...
Oncocyte Presents Confirmatory Data for DetermaIO™ at the American Association for Cancer Research Annual Meeting 2022
11 avr. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
28 mars 2022 08h00 HE
|
Oncocyte Corporation
Poster outlines data showing Oncocyte’s DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer IRVINE, Calif., March 28, 2022 ...
Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
10 mars 2022 16h05 HE
|
Oncocyte Corporation
DetermaRx Revenues and Test Volume Grew 104% and 54%, respectively, in Q4 versus Q3 2021 Development and Co-Marketing Agreement with Thermo Fisher Scientific to Provide Platform and Channel Partner...
Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10
01 mars 2022 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient...
Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
10 févr. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...